Late recovery of renal function by rituximab in a patient with Wegener's granulomatosis

Pediatric Nephrology

Volumn 28, Issue 3, 2013, Pages 511-514

  Malina, Michal ^a,c   Schaefer, Betti ^a   Waldherr, Rüdiger ^b   Wühl, Elke ^a   Schaefer, Franz ^a   Schmitt, Claus Peter ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b Gemeinschaftspraxis fur Pathologie   (Germany)

^c UNIVERSITY HOSPITAL MOTOL   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CREATININE; CYCLOPHOSPHAMIDE; MYCOPHENOLIC ACID; NEUTROPHIL CYTOPLASMIC ANTIBODY; PREDNISOLONE; RITUXIMAB;

ADD ON THERAPY; ADOLESCENT; ARTHRALGIA; ARTICLE; B LYMPHOCYTE; BONE PAIN; CASE REPORT; CELL INFILTRATION; CONVALESCENCE; CREATININE BLOOD LEVEL; CUSHINGOID SYNDROME; DISEASE COURSE; DRUG PULSE THERAPY; DRUG WITHDRAWAL; FEMALE; FEMUR HEAD NECROSIS; FIBROSING ALVEOLITIS; FOCAL GLOMERULOSCLEROSIS; FOLLOW UP; GASTROINTESTINAL SYMPTOM; GLOMERULUS FILTRATION RATE; HEMATURIA; HUMAN; KIDNEY BIOPSY; KIDNEY FAILURE; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; LYMPHOCYTE COUNT; MAINTENANCE DRUG DOSE; MAINTENANCE THERAPY; MONONUCLEAR CELL; MULTIPLE PULMONARY NODULES; OSTEOPENIA; PERITONEAL DIALYSIS; PLASMAPHERESIS; PRIORITY JOURNAL; PROTEINURIA; RELAPSE; REMISSION; SINGLE DRUG DOSE; WEGENER GRANULOMATOSIS;

ADOLESCENT; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; KIDNEY FAILURE, CHRONIC; PERITONEAL DIALYSIS; RECOVERY OF FUNCTION; TIME FACTORS; TREATMENT OUTCOME; WEGENER GRANULOMATOSIS;

EID: 84876288503     PISSN: 0931041X     EISSN: 1432198X     Source Type: Journal    
DOI: 10.1007/s00467-012-2332-4     Document Type: Article

References (15)

1. Grisaru S, Yuen GW, Miettunen PM, Hamiwka LA (2010) Incidence of Wegener's granulomatosis in children. J Rheumatol 37:440-442
2. Akikusa JD, Schneider R, Harvey EA, Hebert D, Thorner PS, Laxer RM, Silverman ED (2007) Clinical features and outcome of pediatric Wegener's granulomatosis. Arthritis Rheum 57:837-844
3. Belostotsky VM, Shah V, Dillon MJ (2002) Clinical features in 17 paediatric patients with Wegener granulomatosis. Pediatr Nephrol 17:754-761
4. Ozen S, Pistorio A, Iusan SM, Bakkaloglu A, Herlin T, Brik R, Buoncompagni A, Lazar C, Bilge I, Uziel Y, Rigante D, Cantarini L, Hilario MO, Silva CA, Alegria M, Norambuena X, Belot A, Berkun Y, Estrella AI, Olivieri AN, Alpigiani MG, Rumba I, Sztajnbok F, Tambic-Bukovac L, Breda L, Al-Mayouf S, Mihaylova D, Chasnyk V, Sengler C, Klein-Gitelman M, Djeddi D, Nuno L, Pruunsild C, Brunner J, Kondi A, Pagava K, Pederzoli S, Martini A, Ruperto N (2010) EULAR/PRINTO/PRES criteria for Henoch-Schönlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part II: Final classification criteria. Ann Rheum Dis 69:798-806
5. Guerry MJ, Brogan P, Bruce IN, D'Cruz DP, Harper L, Luqmani R, Pusey CD, Salama AD, Scott DG, Savage CO, Watts RA, Jayne DR (2011) Recommendations for the use of rituximab in anti-neutrophil cytoplasm antibody-associated vasculitis. Rheumatology (Oxford) 51:634-643
6. Jones RB, Tervaert JW, Hauser T, Luqmani R, Morgan MD, Peh CA, Savage CO, Segelmark M, Tesar V, van Paassen P, Walsh D, Walsh M, Westman K, Jayne DR (2010) Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med 363:211-220
7. Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, Kallenberg CG, St Clair EW, Turkiewicz A, Tchao NK, Webber L, Ding L, Sejismundo LP, Mieras K, Weitzenkamp D, Ikle D, Seyfert-Margolis V, Mueller M, Brunetta P, Allen NB, Fervenza FC, Geetha D, Keogh KA, Kissin EY, Monach PA, Peikert T, Stegeman C, Ytterberg SR, Specks U (2010) Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 363:221-232
8. Cartin-Ceba R, Fervenza FC, Specks U (2012) Treatment of antineutrophil cytoplasmic antibody-associated vasculitis with rituximab. Curr Opin Rheumatol 24:15-23
9. Cohen Tervaert JW (2011) Rituximab in ANCA-associated vasculitis: a revolution? Nephrol Dial Transplant 26:3077-3079
10. Tzaribachev N, Koetter I, Kuemmerle-Deschner JB, Schedel J (2009) Rituximab for the treatment of refractory pediatric autoimmune diseases: a case series. Cases J 2:6609
11. Tamura N, Matsudaira R, Hirashima M, Ikeda M, Tajima M, Nawata M, Morimoto S, Kaneda K, Kobayashi S, Hashimoto H, Takasaki Y (2007) Two cases of refractory Wegener's granulomatosis successfully treated with rituximab. Intern Med 46:409-414
12. Eleftheriou D, Melo M, Marks SD, Tullus K, Sills J, Cleary G, Dolezalova P, Ozen S, Pilkington C, Woo P, Klein N, Dillon MJ, Brogan PA (2009) Biologic therapy in primary systemic vasculitis of the young. Rheumatology (Oxford) 48:978-986
13. Berden AE, Jones RB, Erasmus DD, Walsh M, Noel LH, Ferrario F, Waldherr R, Bruijn JA, Jayne DR, Bajema IM (2012) Tubular lesions predict renal outcome in antineutrophil cytoplasmic antibody-associated glomerulonephritis after rituximab therapy. J Am Soc Nephrol 23:313-321
14. van de Veerdonk FL, Lauwerys B, Marijnissen RJ, Timmermans K, Di Padova F, Koenders MI, Gutierrez-Roelens I, Durez P, Netea MG, van der Meer JW, van den Berg WB, Joosten LA (2011) The anti-CD20 antibody rituximab reduces the Th17 cell response. Arthritis Rheum 63:1507-1516
15. Wilde B, van Paassen P, Witzke O, Tervaert JW (2011) New pathophysiological insights and treatment of ANCA-associated vasculitis. Kidney Int 79:599-612